Oppenheimer lowered the firm’s price target on Zura Bio (ZURA) to $17 from $19 and keeps an Outperform rating on the shares. The firm notes Zura reported Q1 results with tibulizumab continuing to advance. The Phase 2 TibuSURE trial in SSC is active with efforts focused on site contracting and activation. Next up the HS study is slated to begin Q2 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA:
- Zura Bio Reports Q1 2025 Financial Results
- Cautious Hold Rating for Zura Bio Amid Financial Challenges and Clinical Uncertainties
- Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
- Zura Bio price target lowered to $19 from $20 at Oppenheimer
- Zura Bio Limited: 2024 Financial Results and Strategic Progress